An Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months
Latest Information Update: 31 May 2024
At a glance
- Drugs Influenza-virus-vaccine-quadrivalent-Sinovac-Biotech (Primary) ; Influenza virus vaccine trivalent Novavax
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Sinovac Biotech
Most Recent Events
- 24 May 2024 Status changed from recruiting to completed.
- 11 Jan 2023 Planned End Date changed from 10 Apr 2023 to 20 Dec 2023.
- 11 Jan 2023 Planned primary completion date changed from 20 Nov 2022 to 20 Dec 2023.